Urinary tract involvement in peritoneal metastatic disease: Is this a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?
Urinary tract involvement in resectable peritoneal malignancies might require extensive resections and reconstructions in the genitourinary tract during the performance of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), a fact which could impair the postoperative course and survival of these patients. We performed a review of the literature to assess whether urinary tract involvement in patients with peritoneal metastases undergoing CRS and HIPEC could affect the postoperative outcomes with respect to morbidity, mortality and survival rates, identifying a total of 6 retrospective studies addressing these clinical questions. Despite their heterogeneity, the existing studies demonstrate that despite a possible increase in postoperative complications when urological procedures are required as part of cytoreduction, survival outcomes do not seem to be affected. This review therefore concludes that urinary tract 6 in peritoneal metastatic disease is not a contraindication to CRS and HIPEC.